Companion diagnostics

For every 10 cancer patients treated, an average of only half will benefit. For some, the treatment won’t have any effect; others may suffer from serious side effects.1 Roche Diagnostics is working at our industry’s forefront to change this dynamic by enabling physicians to customise therapy to individual patients, whilst helping improve diagnostic accuracy, lab efficiency and patient safety.

In collaboration with leading pharmaceutical companies, we identify and develop innovative companion diagnostics to identify those patients who are likely to respond to specific therapies. Because we recognise the tremendous potential for these solutions, we continue to focus on developing the cutting-edge tools needed to address unmet medical needs.


Helping to deliver the promise of personalised healthcare

  • Tissue diagnostics: no other technology captures the anatomical context that helps determine patient outcomes and enables personalised healthcare
  • Companion tissue tests help determine the best course of treatment
  • The Ventana ALK IHC Rabbit Monoclonal Primary Antibody aids in early detection and treatment decisions for non-small cell lung cancer patients.
Source: Roche Personalized Healthcare brochure, 2011